Beremagene Geperpavec
Brand names: Vyjuvek · Active ingredient: Beremagene Geperpavec
In short: VYJUVEK is indicated for the treatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1)gene.
What is Beremagene Geperpavec used for?
VYJUVEK is indicated for the treatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the
collagen type VII alpha 1 chain (COL7A1)gene.
Beremagene Geperpavec dosage
For topical application on wounds only.
The recommended dose of VYJUVEK gel is based on age (Table 1). VYJUVEK gel is applied topically to wound(s) weekly.
Age Range | Maximum Weekly Dose (PFU) | Maximum Weekly Volume (mL)*
<3 years old | 2×10 9 | 1
≥3 years old | 4×10 9 | 2
PFU=plaque forming unit; mL=milliliter
*Maximum weekly volume is the volume after mixing VYJUVEK biological suspension with excipient gel.
It may not be possible to apply VYJUVEK gel to all the wounds at each treatment visit.
Apply VYJUVEK gel to wounds until they are closed before selecting new wound(s) to treat.
Prioritize weekly treatment to previously treated wounds if they re-open.
If a dose is missed, apply VYJUVEK gel as soon as possible and resume weekly dosing thereafter.
Important Preparation Instructions
Prepare VYJUVEK gel at the pharmacy by mixing the VYJUVEK biological suspension into the excipient gel for immediate use.
The VYJUVEK gel prepared at the pharmacy, should be applied by a healthcare professional (HCP), patient, or caregiver either at a healthcare professional setting (e.g., clinic) or at a home setting.
Individuals who are pregnant should not prepare or apply VYJUVEK gel and should avoid direct contact with the treated wounds or dressings from treated wounds .
Below is the list of supplies needed for VYJUVEK gel preparation:
One (1) carton containing one (1) VYJUVEK biological suspension vial and one (1) excipient gel vial (Figure 1)
Two (2) 18-gauge needles
Two (2) to four (4) 1 mL administration syringes
One (1) 3 mL preparation syringe
Two (2) to four (4) syringe caps
Protective gloves
70% isopropyl alcohol pads
Biohazard container
Labels for administration syringes
Virucidal agent for clean-up
Follow the steps below for VYJUVEK gel preparation.
PREPARE THE PREPARATION SYRINGE
1. Wash hands and put on protective gloves. 2. Remove both vials from the carton and thaw the VYJUVEK biological suspension vial and the excipient gel vial at room temperature for AT LEAST 20 minutes (Figure 1).
Figure 1 Carton containing the VYJUVEK biological suspension vial and excipient gel vial
Note: Visually inspect the vials to ensure both are in liquid form and completely thawed. Excipient gel is more viscous and will take longer to thaw (Figure 2).
Figure 2 Timelapse of excipient gel thaw from 0 minutes to 20 minutes
Note: Once either the VYJUVEK biological suspension or the excipient gel is thawed, do not refreeze.
3. Invert the VYJUVEK biological suspension vial 4-5 times. Do not invert the excipient gel vial. 4. Remove the caps from the vials and clean each vial stopper with a 70% isopropyl alcohol pad. Allow them to dry. 5. Aseptically connect an 18-gauge needle to the 3 mL preparation syringe. 6. …
How to take Beremagene Geperpavec — instructions & advice from the label
Advise the patient or caregiverto read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Advise patients and caregivers of the following precautions prior to and during treatment with VYJUVEK gel:
Avoid direct contact with treated wounds (e.g., touching and scratching) and dressings of treated wounds until the next dressing change following VYJUVEK gel application. In the event of accidental exposure, instruct patients and exposed individuals to clean the affected area .
Wash hands and wear protective gloves when changing wound dressings .
Disinfect bandages from the first dressing change with a virucidal agent, such as 70% isopropyl alcohol, 6% hydrogen peroxide, or <0.4% ammonium chloride, and dispose of the disinfected bandages in a separate sealed plastic bag in household waste. Dispose of the subsequent used dressings and cleaning materials into a sealed plastic bag and dispose in household waste .
Manufactured by:
Krystal Biotech, Inc. 2100 Wharton Street, Suite 701 Pittsburgh, PA 15203 U.S. License No. 2301
VYJUVEK® is a registered trademark of Krystal Biotech, Inc.
© 2026 Krystal Biotech, Inc. All rights reserved. …
Warnings & precautions
Do not take this medicine if: None.
Accidental exposure to VYJUVEK may occur to close contacts and caregivers. VYJUVEK is a genetically modified, herpes-simplex virus type 1 vector-based, replication-deficient, non-integrating gene therapy. VYJUVEK will not replicate in the patient’s cells and does not integrate into the patient cells’ native genetic material. For precautions,
Avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds until the next dressing change.
Wear protective gloves when assisting patients with changing wound dressings and handling the disposal.
In the event of an accidental exposure through a splash to the eyes or mucous membranes, flush with clean water for at least 15 minutes.
Beremagene Geperpavec side effects
The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data described in this section reflects exposure to VYJUVEK gel in a randomized, intra-patient placebo‑controlled study. A total of 31 patients with dystrophic epidermolysis bullosa (DEB), including 30 patients with autosomal recessive DEB and one patient with autosomal dominant DEB received topical administration of VYJUVEK gel to their wounds. The age of the patients ranged from 1 year to 44 years (mean age 17 years). Of the 31 patients, 19 (61%) were pediatric patients (less than 17 years of age), and 11 (36%) were females. Each patient received weekly topical application of VYJUVEK gel at one or more wound sites and placebo at a matching wound site as an intra-subject comparator. The median duration of exposure to VYJUVEK gel was 25 weeks. The most frequent adverse reactions (incidence >5%) observed in the study are summarized in Table 3. There were no discontinuations due to adverse reactions. …
Drug interactions
No drug interaction studies have been performed.
About this medicine
VYJUVEK (beremagene geperpavec-svdt) is a suspension of an HSV-1 vector-based gene therapy, mixed with the supplied sterile excipient gel for topical application on wounds. VYJUVEK is a live, replication defective HSV-1-based vector that has been genetically modified to express the human type VII collagen (COL7) protein. The parental virus for VYJUVEK was a primary isolate, which was subsequently altered using recombinant methods to result in gene deletions and insertions.
VYJUVEK is an opalescent yellow to colorless biological suspension following thaw from its frozen state. Each 1 mL VYJUVEK vial contains 5×10 9
PFU/mL of VYJUVEK in a solution of 0.1 mL/mL Glycerol, 8.0 mg/mL Sodium Chloride, 1.14 mg/mL Sodium Phosphate Dibasic (anhydrous), 0.2 mg/mL Potassium Chloride, 0.2 mg/mL Potassium Phosphate Monobasic.
The excipient gel is a clear viscous solution, following thaw from its frozen state. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fe207c8c-04b4-4fdf-87cf-6dbc7eb6e9c2. Read the full official label on DailyMed.